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Multivitamins and minerals modulate
whole-body energy metabolism and
cerebral blood-flow during cognitive task
performance: a double-blind, randomised,
placebo-controlled trial
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Luca Barella2, Alexandra Carne1, Fiona L. Dodd1, Bernadette C. Robertson1, Joanne Forster1
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Abstract
Background: The brain is by far the most metabolically active organ in the body, with overall energy expenditure
and local blood-supply closely related to neural activity. Both energy metabolism and cerebral vaso-dilation are
dependent on adequate micronutrient status. This study investigated whether supplementation with ascending
doses of multi-vitamin/minerals could modulate the metabolic and cerebral blood-flow consequences of
performing cognitive tasks that varied in difficulty.
Methods: In this randomised, double-blind, placebo-controlled, parallel-groups study 97 healthy females (25–49 y),
who were not selected on the basis of any nutritional parameters, received either placebo or one of two doses of
multivitamins/minerals. Cerebral blood-flow (CBF) parameters in the frontal cortex, and total energy expenditure
(TotalEnergy), carbohydrate and fat oxidation (CarbOxi/FatOxi), were measured during 5 tasks of graded cognitive
difficulty and a control task (5 min per task) using Near-infrared spectroscopy (NIRS) and Indirect calorimetry of
exhaled pulmonary gas (ICa) respectively. Assessments took place 60 min after the first dose and following eight
weeks supplementation.
Results: During task performance supplementation with the first dose of micronutrients led to a dose-dependent
increase in TotalEnergy and FatOxi throughout the post-dose assessment period following the higher dose, and
increases in the total concentration of haemoglobin, a proxy measure for CBF, during task performance following
the lower dose of vitamins/minerals (also containing coenzyme-Q10). Chronic supplementation over 8 weeks led to
a dose-dependent increase in TotalEnergy during the task period. There were no interpretable effects on mood or
cognitive performance.
(Continued on next page)
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Conclusions: These results show that acute supplementation with micronutrients in healthy adults can modulate
metabolic parameters and cerebral blood flow during cognitive task performance, and that the metabolic
consequences are sustained during chronic supplementation. These findings suggest that both brain function and
metabolism are amenable to micronutrient supplementation, even in adults who are assumed to have nutritional
status typical of the population.
Trial registration: ClinicalTrials.gov - NCT02381964.
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Background
Whilst the brain represents only approximately 2 % of
body weight, it receives 11 % of cardiac output and ac-
counts for more than 20 % of the body’s total energy ex-
penditure [1]. Most of the brain’s energy requirement is
expended on neural signalling, with the high baseline
levels of energy expenditure during resting wakefulness
being augmented by comparatively small increases dur-
ing focussed activity [1, 2]. During these periods of
neural activity metabolic substrates (glucose/oxygen)
cross the blood brain barrier and are delivered, on
demand, to active brain areas via dilation of the local
vasculature. Nitric oxide is a key mediator of this ‘neuro-
vascular coupling’ between neuronal activity and in-
creased blood supply in active tissue [3, 4] and is
released from cortical neurons in an activity-dependent
manner [5]. The direct local increases in blood flow or
metabolic substrates during local activity provide the
proxy markers of activity for brain imaging techniques
such as functional magnetic resonance imaging (fMRI)
and positron emission tomography (PET). Interestingly,
several studies have used indirect calorimetry (ICa) of
exhaled pulmonary air to investigate changes in whole-
body metabolism during brain activity. These studies
have demonstrated increased overall energy expenditure
during the performance of cognitive tasks [6] and during
rapid eye movement (REM) sleep, as compared to other
sleep stages [7], and a shift towards fat oxidation during
the middle and later stages of a chess game [8].
Vitamins and minerals play both direct roles in brain
function (e.g. via neurotransmitter synthesis, receptor
binding, membrane ion pump function) as well as indir-
ect roles, for instance via their involvement in energy
metabolism and the modulation of cerebral blood supply
[9, 10]. With regards cellular energy production, most of
the 13 vitamins and a number of minerals play direct or
indirect roles in mitochondrial function [10–12]. As an
example, the water-soluble B vitamins play ubiquitous
and essential interacting roles as coenzymes and precur-
sors in the majority of cellular functions. Of particular
relevance here vitamins B1, B2, B3, B5 are essential co-
factors in mitochondrial aerobic respiration and cellular
energy production via their roles in the tricarboxylic acid
cycle, the electron transport chain and the formation of
adenosine triphosphate (ATP), the cell’s energy currency;
whereas vitamins B6, B9, and B12 play essential roles in
all aspects of one-carbon metabolism [10, 12–14]. Simi-
larly, coenzyme Q10 (CoQ10) is an essential coenzyme
required alongside the vitamins for the mitochondrial
production of ATP via oxidative phosphorylation.
CoQ10, which is also a potent antioxidant, is synthesised
endogenously at a low rate, and its level can be aug-
mented from dietary sources. It has been noted that de-
ficiencies in both the B vitamins and CoQ10 are
associated with fatigue and a number of conditions re-
lated to compromised mitochondrial function [10, 13, 15].
The role of multiple vitamins in overall somatic energy
production has been investigated directly in a single study
conducted in 87 obese females which used ICa to assess
the effects of 26 weeks supplementation with multi-
vitamins/minerals or placebo on energy expenditure. The
results showed that supplementation was associated with
a significant increase in resting energy expenditure and fat
oxidation [16].
As well as pivotal roles in mitochondrial energy pro-
duction, both vitamins and CoQ10 are also associated
with cardiovascular functioning, and therefore, by impli-
cation, the delivery of metabolic substrates to the brain.
As an example, the status of vitamin C [17], vitamin D
[18] and B vitamins [19] have all been shown to be re-
lated to peripheral blood flow as indicated by measures
of endothelial function. Similarly, single doses of vita-
mins B9, C, E and C/E combined have all been shown to
increase vasodilation, as measured by flow mediated
dilation, in groups with disease or dietary manipulation
related endothelial dysfunction [20–23]. Similarly, there
is evidence that longer term supplementation with vita-
min C [24–26], vitamin B12 [27], vitamin B9 [28] and
vitamin D [29–31] can improve endothelial function in
groups with poor endothelial function, cardio-metabolic
disorders or a deficiency in the specific vitamin. In the
case of CoQ10, a recent meta-analysis of the results of
five methodologically adequate studies [32] suggested
that supplementation with CoQ10 can also engender im-
provements in endothelial function and other cardiovas-
cular parameters. The underlying hypothesis for the
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vasodilatory effects of these micronutrients typically re-
lates to their antioxidant properties. However, in the case
of vitamin C [24, 25], vitamin B9 [28]. and CoQ10 [32],
specific roles in the synthesis of nitric oxide or the activity
of nitric oxide synthase have been identified.
The relationship between micronutrients and energy
production/blood flow becomes most pertinent in light
of evidence suggesting that a substantial proportion of
the general population of developed countries are defi-
cient in one or more vitamins and minerals [12, 33, 34].
The reversal of marginal insufficiencies/deficiencies may
well underlie recent demonstrations of improved mood
or cognitive performance following supplementation
with multi-vitamins/minerals in healthy cohorts of chil-
dren [35, 36] and adults [37, 38]. Given the above, the
current study investigated whether supplementation
with multi-vitamins/minerals (± CoQ10) could modulate
the increases in energy expenditure and concentrations
of haemoglobin, a proxy measure of local cerebral blood
flow (CBF), associated with differing intensities of cogni-
tive tasks, using ICa and near-infrared spectroscopy
(NIRS) respectively. This randomised, double-blind,
placebo-controlled, parallel-groups study therefore in-
volved the monitoring of metabolic parameters and CBF
parameters during five tasks that exerted varying levels
of cognitive demand and a somatically matched control
task.
Methods
Design
The study employed a randomised, double-blind,
placebo-controlled, parallel groups design with energy
metabolism, and cerebral hemodynamics during cog-
nitive tasks being measured following a single dose
(Day 1) and after eight weeks (Day 56) supplementa-
tion with one of two multivitamin/mineral supple-
ments or placebo. In this exploratory study both the
metabolic and CBF parameters were considered pri-
mary outcomes and all other measures secondary
outcomes.
Treatments
The three treatment groups comprised:
 Supradyn® 1RDA + CoQ10, containing vitamins/
minerals at levels up to 100 % of the 2008 European
Union recommended dietary allowances (RDA), plus
4.5 mg CoQ10 (1RDA + Q10).
 Supradyn® 3RDA, containing vitamins and minerals
at levels up to 300 % (water soluble vitamins only)
of the 1990 European Union RDAs (3RDA).
 Placebo matched for appearance, taste, and odour
(composed of excipients from the active formulae:
talc, magnesium stearate, microcrystalline cellulose).
The active constituents of the multivitamin/mineral
interventions are shown in Table 1.
The interventions were provided in a single bottle
containing film coated tablets sufficient for a 63 day sup-
plementation period. All treatments were prepared and
bottled by the manufacturer in accordance with a
computer-generated randomisation list and delivered to
the investigational site identified only by their random-
isation code. Participants were allocated sequentially to
the randomisation code list. One dose of the interven-
tion was taken orally, with water, once a day over a
period of 56 days. Compliance was assessed with treat-
ment diaries, pill counting, and an interim (~Day 28)
phone conversation.
Participants
A total of 106 females in the age range 25 to 49 years
were randomised. Following drop-outs and exclusions,
Table 1 Composition of the 1RDA + Q10 and 3RDA interventions
Active Units 1RDA1+CoQ10 3RDA2
Vitamin A μg 800 800
Vitamin B1 mg 1.1 4.2
Vitamin B2 mg 1.4 4.8
Vitamin B6 mg 1.4 6
Vitamin B12 μg 2.5 3
Vitamin C mg 80 180
Vitamin D3 μg 5 5
Vitamin E mg 12 10
Vitamin K1 μg 25 30
Biotin μg 50 450
Folic acid μg 200 600
Niacin mg 16 54
Pantothenic acid mg 6 18
Calcium mg 120 120
Copper mg 1 0.9
Iodine μg 150 75
Iron mg 14 8
Magnesium mg 80 45
Manganese mg 2 1.8
Molybdenum μg 50 45
Selenium μg 50 55
Zinc mg 10 8
Coenzyme Q10 mg 4.5
Phosphorus mg 126.3
Chromium μg 25
Fluoride mg 1.5
1Up to 1 RDA as per EU directive 2008/100/EC (2008) 2 Up to 3 RDAs as per EU
directive 90/496/EEC (1990)
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as identified during a blind data-review meeting, a total
of 87 participants who had provided a full set of data on
Day and Day 56 were included in the statistical analyses.
Participant demographics and dispositions are shown in
Table 2/Fig. 1.
All participants had a body mass index (BMI) in the
range of 18.50-34.99 kg/m2 and they did not exhibit any
clinically relevant deviations from normal blood pres-
sure, pulse rate, respiratory rate and body temperature.
All participants also self-reported that they were healthy,
did not currently take any pharmaceutical treatments
(with exception of oral contraceptives, or other routine
medications to treat benign conditions) and did not have
a history or current diagnosis of any relevant disease,
including neurological or psychiatric diseases, signifi-
cant head trauma, migraines within the last five years,
or drug/alcohol abuse. Participants also self-reported
that they were not pregnant or lactating and, if rele-
vant, were using a medically acceptable form of birth
control; that they did not smoke or consume excessive
daily levels of caffeine (>500 mg caffeine per day); that
they had not taken significant quantities of dietary
supplements within the last 4 weeks. Participants
agreed to abstain from alcohol for 24 h and to fast
(with the exception of water) for 12 h before each
visit, and to abstain throughout the trial from intake
of any herbal extracts or dietary supplements. The
participants’ continued compliance with the inclusion/
exclusion criteria was confirmed at the start of each
visit to the laboratory.
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all proce-
dures involving human subjects/patients were approved
by the Northumbria University Faculty of Health and
Life Sciences ethics committee. Written informed con-
sent was obtained from all subjects. The trial was regis-
tered on ClinicalTrials.gov - Identifier: NCT02381964.
Measures
Energy metabolism - indirect calorimetry (ICa)
Oxygen uptake and carbon dioxide production were
measured from expired pulmonary air using an on-line
gas analysis system (Metalyzer 3B, Cortex, Leipzig,
Germany). These data were used to calculate total
energy expenditure (TotalEnergy), and fat and carbohy-
drate metabolism (FatOxi and CarbOxi respectively)
using the standard formulae [39]. During the sampling
period subjects breathed into a mask covering the nose
and mouth; this was connected to the Metalyzer via
falconia tubing. All subjects were familiarised with the
procedure before commencing the trial. The Metalyzer
3B also collected heart rate data.
Cerebral blood-flow parameters - near- infrared
spectroscopy (NIRS)
NIRS is non-invasive brain imaging technique predicated
on the absorption by oxygenated (Oxy-Hb) and deoxy-
genated (Deoxy-Hb) hemoglobin of differing wave-
lengths of infra-red light, introduced through the intact
scalp/skull. Continuous-wave NIRS (CW-NIRS) can be
used to assess acute changes in local CBF, as indexed by
concentration changes in total hemoglobin during a sin-
gle continuous recording session. Given that CW-NIRS
generates concentration change data that is intrinsically
baseline-adjusted to the concentration immediately prior
to the first data point in the recording session, it cannot
Table 2 Group demographics, including the results of one-way ANOVAs confirming equivalence on all parameters
1RDA + Q10
N = 32
3RDA
N = 31
Placebo
N = 34
Task period Mean SEM Mean SEM Mean SEM F p
Age (years) 32.97 1.26 33.65 1.26 33.38 1.32 0.07 0.93
Height (cm) 166.09 0.92 166.13 1.15 165.24 1.17 0.22 0.80
Weight (kg) 66.08 1.70 67.55 1.96 64.39 1.40 0.88 0.42
BMI (kg/m2) 23.94 0.57 24.55 0.77 23.64 0.55 0.53 0.59
Fruit and veg (portions per day) 3.98 0.24 3.87 0.27 4.62 0.29 2.24 0.11
Physical activity (hours per week) 3.28 0.53 3.42 0.70 3.79 0.47 0.22 0.80
Weekly alcohol consumption (units) 6.5 0.81 5.29 0.82 6.47 0.98 0.6 0.55
Daily caffeine consumption (mg) 158.42 20.51 167.59 20.92 169.21 19.14 0.08 0.92
Systolic blood pressure (mm/Hg) 114.47 1.57 117.55 1.74 116.47 1.53 0.92 0.40
Diastolic blood pressure (mm/Hg) 78.16 1.38 77.16 1.57 78.15 1.23 0.17 0.85
Heart rate (bpm) 68.63 1.87 66.16 1.95 69.56 2.09 0.78 0.46
Respiratory rate 15.44 0.51 14.55 0.66 14.38 0.50 1.03 0.36
Tympanic temperature 36.82 0.07 36.93 0.05 36.87 0.07 0.66 0.52
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be used to quantify gross changes in CBF haemoglobin
parameters that take place between two separate record-
ing sessions. In this instance the change from baseline
data generated by the NIRS system was subjected to a
second baseline adjustment by creating ‘change from
baseline’ data with respect to the 5 min of resting NIRS
data collected immediately prior to consumption of the
treatment on each day – this provided a more accurate
baseline measure of immediately pre-treatment NIRS
parameters.
When assessed by NIRS, the increase in cerebral blood
flow (CBF) in the surface layers of the cortex during lo-
calized neural activity is typically seen as an increase in
the concentration of Oxy-Hb and the total concentration
of hemoglobin (Total-Hb) and comparative decrease in
Deoxy-Hb [40] with both parameters suggested to cor-
respond strongly with the functional magnetic resonance
imaging (fMRI) blood oxygen level dependent (BOLD)
signal [41, 42].
In this instance, relative changes in the absorption of
near-infrared light were measured at a time resolution of
10Hz using a 12-channel Oxymon system (Artinis
Medical Systems B.V.). The system emitted two nominal
wavelengths of light (~765- and 855 nm) with an
emitter/optode separation distance of 4 cm. The differ-
ential path-length factor was adjusted according to the
age of the participant using the proprietorial software.
Relative concentration changes in Oxy-Hb, Deoxy-Hb
and Total-Hb were calculated by means of a modified
Beer-Lambert law [43] using the proprietorial software.
Given the extended recording period and the investiga-
tional aims, a simple two emitter/optode pair configur-
ation was utilised (i.e. 2 channels). The emitter/optode
pairs were positioned over the left and right frontal cor-
tex using a standard optode holder headband, which
separated the pairs from each other by 4 cm. Each pair
therefore collected data from an area of prefrontal cor-
tex that included the areas corresponding to the Inter-
national 10–20 system Fp1 and Fp2 EEG positions. Prior
to the primary analysis described below, ANOVAs in-
cluding hemisphere (i.e. optode) as an additional factor
(i.e. hemisphere x day x epoch x treatment) were carried
out. In the absence of any treatment related interactions
with ‘hemisphere’, data from the two optodes were sim-
ply averaged for all of the analyses reported in this
paper. The methodology described above been used pre-
viously to demonstrate the effects of a number of nutri-
tional interventions on cerebral cerebral blood-flow
parameters [44–46].
Cognitive tasks
A range of cognitive tasks of varying levels of difficulty,
plus a somatically matched control task, were delivered
on laptop computers via the Computerised Mental
Performance Assessment System (COMPASS) software
(Northumbria University, UK). The order of the 5 cogni-
tive tasks and the control task were counterbalanced
across participants, with each individual participant
3 x drop-outs
Subjects Randomized  
N = 106
1RDA CoQ10
N = 35
3RDA
N = 35
Placebo
N = 36
Day 1
N= 32
3 x  protocol 
violations
Day1
N= 31
Day 1
N= 34
Day 56
N= 30
1 x con-meds
1 x drop-outs
Day 56
N= 29
Day 56
N= 28
2 x technical 
issues
1 x con-meds
2 x drop-outs
4 x  protocol 
violations
2 x  protocol 
violations
Fig. 1 Subject disposition flowchart
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completing the tasks in the same order during each as-
sessment. Each task was of 5 min duration, with a two
minute resting period between tasks. The selection of
tasks comprised:
Serial subtractions (3 s, 7 s and 17 s) Serial subtraction
tasks (Serial 3 s and Serial 7 s) have been used previously
to elicit hemodynamic responses in the frontal cortex in
a number of NIRS [45, 47] and fMRI [48] studies. In this
instance modified, five minute versions of the Serial 3 s
and Serial 7 s tasks, and a novel Serial 17 s task were
employed. For each task a standard instruction screen
informed the subject to count backwards in threes
(sevens or seventeens) from a given randomly generated
number between 800 and 999, as quickly and accurately
as possible. Subjects were also instructed verbally that if
they made a mistake they should carry on subtracting
from the new incorrect number. Each three-digit re-
sponse was entered via the linear number keys with each
digit being represented on screen by an asterisk. Pressing
the ‘enter’ key signalled the end of each response and
cleared the three asterisks from the screen. The task was
scored for total number of subtractions and number of
errors. In the case of incorrect responses, subsequent
responses were scored as positive if they were correct in
relation to the new number.
3-back task N-Back tasks have been used widely in
brain imaging studies probing brain activation, including
in the frontal cortex, during working memory tasks [49].
Here the most difficult 3-back version was utilised. A
continuous string of letters (upper and lower case; dis-
play time 500 msec; inter-stimulus interval of 2.5 s) was
presented in the centre of the screen for 5 min. For each
stimulus, subjects were instructed to indicate whether
this was the same letter that appeared three letters be-
fore or not by pressing ‘yes’ and ‘no’ buttons on the re-
sponse box as rapidly as possible. A third of all stimuli
(40/120) represented target pairs. The task was scored
for percentage of correct responses and reaction times
to correct stimuli.
Stroop task The Stroop task is widely used as a measure
of selective attention and executive function. Perform-
ance of the task activates multiple brain regions includ-
ing the frontal cortex [50, 51]. In the five minute
computerised version of the Stroop task employed here
words describing colours (GREEN, BLUE, RED,
YELLOW) were randomly presented in a congruent
(e.g., GREEN presented in green text etc.) or incon-
gruent coloured text (e.g., GREEN presented in blue
text etc.). For each of the stimuli subjects were
instructed to respond to the colour of the text the
word was presented in, by pressing one of the four
corresponding coloured buttons on the response pad.
The task was scored for total % correct and reaction times
to correct congruent and incongruent responses.
Key tapping control task A 5 min control task, somat-
ically matched to the task that requires the most phys-
ical movement (Serial 3 s) was employed to control for
the contribution of physical activity to the measures of
metabolism and CBF. Subjects repeatedly made three
keyboard key presses at the average rate of perform-
ance of the Serial 3 s task, plus 1 standard deviation,
for 5 min. The rate of completion was controlled by
a metronome tone.
Other measures
Subjective difficulty and mental fatigue ratings Visual
analogue scales were used to assess the difficulty (“How
difficult did you find the task that you have just com-
pleted?”) and the subjects’ subjective levels of mental fa-
tigue (“How mentally fatigued do you feel right now?”)
following completion of each task. Participants indicated
their answer to the question by positioning an ‘x’ on a
line anchored “Not at all” and “Extremely” with the
mouse/cursor. Each VAS was scored as % along the line
towards “Extremely”.
Bond-lader mood scales [52] Prior to and following
the cognitive tasks, mood was assessed using ‘Alert’,
‘Content’ and ‘Calm’ factors derived from the Bond-
Lader visual analogue mood scales.
Energy visual analogue scales (Energy VAS) Prior to
and following the cognitive task period, visual analogue
scales were completed which assessed (from ‘very low’ to
‘very high’) the subjects’ self-ratings of ‘concentration’,
‘mental stamina’ and ‘physical stamina’. Scales anchored
at either end by ‘not at all’ and ‘extremely’ also assessed
the subjects’ self-rated levels of being ‘mentally tired’
and ‘physically tired’. All VAS were scored as % along
the line towards ‘very high’/’extremely’.
Nutritional status
Nutritional status was assessed before and after the
supplementation period with reference to serum/
plasma concentrations of homocysteine, vitamin C,
vitamin E, vitamin D (25-hydroxy vitamin D3), iron,
zinc and coenzyme Q10. A total of 18 ml whole
blood was collected from each participant in 3 x 6 ml
ethylenediaminetetraacetic acid (EDTA). Analysis of
the plasma for vitamin E (alpha-tocopherol), coen-
zyme Q10 (ubichinone-10) and vitamin C (ascorbic
acid) was then undertaken using high-performance li-
quid chromatography (HPLC); homocysteine levels
were analysed using chemiluminescence immunoassay
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(CLIA); and vitamin D (25-hydroxy Vitamin D3) levels
were assessed using liquid chromatography-tandem mass
spectrometry (LC-MS/MS). A further 4 ml whole blood
was collected in 4 ml vacutainer serum tubes for the ana-
lysis of iron and zinc levels using photometry. All analyses
were undertaken by Labor Dr. Limbach und Kollegen
(Heidelberg, Germany).
Procedure
Participants attended the Brain, Performance and Nutrition
Research Centre laboratory (Northumbria University),
having fasted for 12 h, on three separate mornings.
The practice visit comprised the obtaining of informed
consent, the collection of demographic and medical
history information and review of conformity to the
inclusion and exclusion criteria. Vital signs, height,
weight (plus calculation of BMI) were measured, and,
where applicable, a confirmatory pregnancy test was
carried out. Following screening, participants were
instructed in the completion of the cognitive tasks,
and were allocated their counterbalanced cognitive task
order. They then underwent a full ICa/NIRS/cognitive
assessment, as described below for Day 1 and Day 56,
with the exception that the ICa and NIRS recording
started 10 min before the cognitive task period rather
than 70 min before (to allow for treatment absorption) on
the subsequent days.
Within 28 days of the practice day participants attended
the laboratory for the Day 1 assessment. Following con-
firmation of compliance with all inclusion/exclusion
criteria, and the measurement of vital signs, partici-
pants were randomized to their treatment group, after
which a venous blood sample was collected. Once the ICa
mask and NIRS were in place, and the proper functioning
of the equipment had been confirmed, the participant sat
for a 10 min resting ICa and NIRS measurement, the last
5 min of which was used as the pre-dose baseline measure
for the CBF parameters. Once the participant had con-
sumed their day’s treatment they sat quietly for 60 min,
the last 5 min of this period was used to calculate the pre-
task, resting-period ICa parameters. Participants then
completed the Bond-Lader mood scales and ‘energy’ visual
analogue scales. The six x five minute tasks were then
completed in the counterbalancing order allocated to the
participant, with a two minute rest period between each
task. Finally, the participant completed the Bond-Lader
mood scales and Energy VAS. NIRS data was collected
continuously throughout the entire assessment. The Day
56 assessment was identical to that on Day 1. The running
order of the Day 1/56 assessments are shown in Fig. 2.
Statistical analyses
Prior to commencement the sample size required for the
study was calculated using G*Power 3 with respect to
the medium effect size (f = 0.24) seen with similar nutri-
tional interventions (e.g. polyphenols) using similar as-
pects of methodology. In order to exceed power of 0.8
for the measures which were repeated six times per as-
sessment (e.g. ICa) a sample size of 30 participants per
group was required, with measures that exceeded this
number of repetitions having greater power.
Metabolic and CBF parameter data
Data from the metabolic parameters (FatOxi, CarbOxi,
TotalEnergy) were collapsed into scores representing the
average during 8 separate five minute epochs: compris-
ing, pre-dose baseline, pre-task resting period, control
task, and the five cognitive tasks.
The NIRS data, averaged across the left and right
optodes, was baseline adjusted with regards the 5 min
pre-dose baseline measure for the respective day. Data
collected following consumption of the treatment was
collapsed (i.e. the mean score was calculated) into: 11 x
five minute epochs spanning the 60 min resting absorp-
tion period (data collected during completion of the
mood scales was discarded), 6 x five minute epochs for
the control task and each of the cognitive tasks, and 5 x
two minute epochs for each of the rest periods between
tasks (see Fig. 4).
Prior to the main analysis. in order to simply confirm
that increasing task demands were associated with sig-
nificant changes in metabolic and NIRS parameters irre-
spective of treatment, change from resting pre-task
baseline data collected on Day 1 and Day 56 were ana-
lysed by two-way ANOVA (Day 1/56 x task). These data
and results are presented in Additional file 1: Table S1
and Figure S1 in the online materials.
Given the exploratory nature of this study, in order to
protect against potential Type II errors, no correction
was made for the number of separate linear-mixed
models (metabolic data - 3 in total) and ANOVA (NIRS
data – 3 in total) analyses described below.
Effects of multivitamins/minerals on metabolic pa-
rameters The data for each individual metabolic param-
eter (FatOxi, CarbOxi, and TotalEnergy) from Day 1 and
Day 56 were analysed separately using the linear mixed-
effects models (MIXED) procedure in SPSS 21.0. This
analysis is appropriate in repeated measures designs that
include a baseline covariate as it accounts for the correl-
ation between data points taken from the same subject
and allows for missing data across time points (using
maximum likelihood to estimate missing data to pro-
duce unbiased full datasets with no loss of power). In
each of the separate models subject was entered as a
random effect and condition, day, task period and their
interactions entered as fixed factors. The resting baseline
data collected prior to taking the treatment on Day 1
Kennedy et al. Nutrition & Metabolism  (2016) 13:11 Page 7 of 16
was entered as a covariate in the analysis of each out-
come. Post-hoc, Bonferroni adjusted comparisons be-
tween the means from each of the multivitamin
conditions and the placebo condition were carried out
to explore any significant main or interaction effects
from the primary analysis.
NIRS parameters (Day 1 and Day 56) The NIRS sys-
tem utilised here generates ‘change in concentration’
data during a given recording session, rather than quan-
titative data, and therefore does not generate data that
can be meaningfully used as a pre-treatment covariate.
The analysis adopted here for each individual NIRS par-
ameter (Oxy-Hb, Deoxy-Hb, Total-Hb) was therefore via
separate three-way ANOVAs (Day1/56 x treatment x
epoch) of change from baseline (calculated from the
relevant day’s immediately pre-treatment rest period)
data from each of the 22 epochs spanning the absorption
and task periods (see above and Fig. 2.). The primary
analysis was via planned comparisons, carried out using
t tests calculated with MSError from the ANOVA, which
were conducted between placebo and the two multivita-
min treatments on means from each epoch. These com-
parisons were Bonferroni-adjusted to allow for any
inflation of Type I errors due to violations of the spher-
icity assumption [53]. Only those planned comparisons
associated with a significant effect on the relevant
ANOVA are reported.
A further similar secondary analysis of data solely from
the six task periods was conducted to identify any effects
of the treatment related to increasing task demands.
Cognitive, mental fatigue, task difficulty and mood/energy
outcomes
The cognitive outcome data (accuracy and speed of per-
formance from each of five tasks – i.e. 10 outcomes in
total) from Day 1 and Day 56 were explored with individ-
ual two-way (treatment x day) ANOVAs. Subjective men-
tal fatigue and difficulty ratings acquired after
performance of the tasks were explored with two-way
(treatment x task) mixed ANOVAs of data from the indi-
vidual day. Mood/energy outcome data were analysed
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Fig. 2 Assessment schedule on Days 1 and 56. Both ICa and NIRS data-collection started with a 10 min pre-dose recording period, the last five
minutes of which was used as the baseline measurement. NIRS data was then collected continuously throughout. Following consumption of the
day’s treatment participants sat quietly for 60 minutes, with data from the last five minutes of this period used as the ICa resting measurement.
Participants then completed the control task, and the five cognitive tasks, in counterbalanced order, with a two minute resting period between
each five minute task period
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with two-way (treatment x before/after tasks) mixed
ANOVAs of data from the individual days. Post-hoc com-
parisons (Bonferroni adjusted) were conducted on data
from each day for those measures that reached
significance.
Nutritional parameters
Analysis of the nutritional blood analyte parameters was
primarily by one-way ANCOVA of Day 56 data, using
the corresponding Day 1 (pre-treatment) data as covari-
ate. Separate one-way ANOVAs of Day 1 and Day 56
data were also conducted to confirm the equivalence of
the groups pre-treatment, and post-treatment group dif-
ferences on any measure.
Results
Data and results with regards the effects of differing task
demands on all subjective, metabolic and CBF outcomes,
irrespective of treatment, are presented in the online
materials in Additional file 1: Figure S1 and Table S1.
Effects of multivitamins/minerals on metabolic
parameters
Fat oxidation – there was a significant interaction between
treatment and Day 1/56 [F (2, 270) = 6.393, P < 0.05]. Ref-
erence to the post-hoc comparisons between means
showed that Fatoxi was significantly increased following a
single dose of the 3RDA treatment on Day 1 (p < 0.01),
with no significant differences evident after 8 weeks ad-
ministration (Day 56).
Carbohydrate oxidation – there was a significant inter-
action between treatment and Day 1/56 [F (2, 276) = 9.9,
P < 0.01]. However, this effect represented opposite,
non-significant patterns on the two days, and reference
to the post-hoc comparisons showed that there were no
significant differences between the active treatment and
placebo means on either day (all, P > 0.1).
Total energy - there was a significant main effect of
treatment with regards Total Energy [F (2, 82 = 4.354, P <
0.05] with consumption of the 3RDA treatment resulting
in increased energy expenditure during task performance
both after a single dose and 8 weeks supplementation
[Day 1 (P < 0.05), Day 56 (P < 0.01)].
Significant effects on the ICa measures are presented
graphically in Fig. 3, with an additional illustrative
graphic representation of the data for each task period.
Data are presented in online Additional file 1: Table S2.
Effects of multivitamins/minerals on CBF parameters
Reference to the ANOVA of the combined Day 1/Day
56 NIRS data showed that there was a significant inter-
action between epoch, day and treatment for Total-Hb
[F (42,1617) = 1.521, P < 0.05]. Reference to the Bonfer-
roni adjusted planned comparisons of data from each of
the 22 epochs showed that CBF, as indexed by Total-
Hb concentrations, was significantly increased during
the 2nd, 3rd , 5th and 6th task periods (all P < 0.01)
on the 1st day of treatment following the 1RDA +
Q10 treatment. There were no significant differences
associated with the 3RDA treatment or during any
epoch following either treatment on Day 56.
The pattern of effects in terms of Oxy-Hb was largely
the same (epoch x day x treatment interaction,
[F(42,1617) = 1.396, P < 0.05]). Following a single dose
of the 1RDA + Q10 treatment, concentrations of Oxy-
Hb were increased during the 2nd, 3rd, 5th and 6th task
periods (all P < 0.01) on Day 1. Additionally Oxy-Hb
was also elevated during the rest period between the 5th
and 6th task periods following 1RDA + Q10 (P < 0.05)
and during a single task period following the 3RDA
treatment (1st Day, 6th task period - P < 0.01). There
were no significant differences during any epoch follow-
ing either treatment on Day 56.
There were no significant effects either with regards
Deoxy-Hb. Mean data (+ SEM) for each epoch on both
days for Total-Hb, Oxy-Hb and Deoxy-Hb are shown in
Fig. 4.
Effects of multivitamins/minerals on cognitive
performance, mood and VAS
There were no significant differences in task perform-
ance following either acute or chronic administration
of the treatments with the exception of a main effect
on 3-Back Correct across both days [F (2,81) = 4.21,
P < 0.05]. Reference to the comparisons between pla-
cebo and treatment means showed that this effect
represented more correct responses following placebo
in comparison to the 1RDA + Q10 treatment (both
days, P < 0.05). The cognitive data are presented in
Additional file 1: Table S3 in the online materials.
There were no significant effects of treatment on rat-
ings of either mental fatigue or task difficulty following a
single dose (Day 1) or mental fatigue following 8 weeks
administration. However, there was a significant differ-
ence evinced in terms of perceived difficulty ratings on
Day 56 (treatment x task interaction, [F (10,365) = 2.31,
P < 0.05]), with both multivitamin treatment groups
(P < 0.01) rating the 3-Back task as having been more dif-
ficult in comparison to the placebo group. However, it
may be notable that this finding was as a result of a sharp
drop in difficulty ratings (as compared to other tasks and
data from Day 1) restricted to this one task in the placebo
condition. Subjective difficulty and mental fatigue out-
come data (+SEM) for Day 1 and Day 56 are presented in
Additional file 1: Table S4 in the online materials.
There were no significant effects on the Bond-Lader
mood scales or Energy VAS.
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Nutritional status parameters
ANOVA of baseline data (Day 1 pre-dose) showed that
the groups did not differ significantly in terms of any
nutritional status parameter at the outset of the study.
However, there was a trend towards such an effect with
regards CoQ10 levels, with inspection of the groups
means suggesting that this was as a consequence of nu-
merically higher levels in the 1RDA + Q10 group than
the other two groups prior to treatment. The primary
analysis (ANCOVA of Day 56 data using Day 1 as covar-
iate) showed that by Day 56 both vitamin D3 and homo-
cysteine levels were significantly modulated by treatment
(vitamin D3 [F (2,75) = 4.13, P < 0.05], homocysteine
[F (2,75) = 8.3, p < 0.001]). Both multivitamin treatments
resulted in elevated vitamin D3 levels (1RDA + CoQ10,
P < 0.05 – 3RDA, P < 0.01]) and reduced homocysteine
levels (1RDA + CoQ10, P < 0.05 – 3RDA, P < 0.001]).
A confirmatory analysis of micronutrient levels using
data solely from Day 56 showed that, as well as signifi-
cantly higher levels of vitamin D3 and lower levels of
homocysteine in both multivitamin groups, CoQ10
levels were also significantly higher in the 1RDA + Q10
group post-treatment (P < 0.05). Data for the nutri-
tional parameters from Day 1 and Day 56 (+SEM) are
shown in Table 3.
Discussion
The results of the current study demonstrate that the
administration of single doses of vitamins and minerals
(± CoQ10) can modulate whole-body metabolic parame-
ters and frontal cortex CBF hemodynamic responses
during the performance of cognitive tasks of graded dif-
ficulty. The modulation of metabolic parameters was
also seen following 8 weeks administration.
With regards to the metabolic parameters, the multi-
vitamin/mineral treatment had a dose dependent effect,
with significant modulation only achieved following the
treatment containing the higher (3RDA) of two doses of
water soluble vitamins. This treatment resulted in both
increased fat oxidation (FatOxi) and increased total en-
ergy expenditure (TotalEnergy), as assessed using indir-
ect calorimetry of exhaled pulmonary gas. These effects
were seen throughout the cognitive task period which
commenced 60 min post-dose. The increase in total en-
ergy expenditure was also sustained, and consolidated, at
the end of the 8 week treatment period. Whilst not
having a significant impact on metabolism, the lower
dose of vitamins/minerals with added coenzyme Q10
(1RDA + Q10) increased the CBF hemodynamic re-
sponse in the frontal cortex during tasks that activate
this brain area following a single dose. In this case both
Fig. 3 Acute and chronic effects of the multivitamin treatments on metabolism. with Bonferroni corrected post-hoc comparisons to placebo. The
graphs on the left show the treatment x day interaction with regards FatOxi and the main effect of treatment on TotalEnergy. The graphs on the
right show the data broken down by task for illustrative purposes. All data are adjusted means (+SEM), derived from the linear mixed-effects
models analysis incorporating the Day 1, pre-treatment baseline measure as a covariate. t, p <0.1; *, p < 0.05; **, p < 0.01; ***, p < 0.001 from the
post-hoc comparisons between the two active treatments and placebo
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Total-Hb, a measure of overall local CBF, and Oxy-Hb
were increased, with no significant effect on concen-
trations of Deoxy-Hb. Interestingly, the pattern of
hemodynamic responses was similar, if less striking, in
the 3RDA group (and reached statistical significance
during several tasks prior to the Bonferroni corrections).
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There was no evidence of acute modulation of
hemodynamic parameters as a consequence of the day’s
dose of the treatment after 8 weeks administration of ei-
ther treatment. However, as noted above, CW-NIRS
generates concentration change, rather than quantitative
data, and therefore only provides a measure of acute
changes in CBF hemodynamics during each discrete re-
cording session. It therefore provides no direct measure
of any changes that have taken place between recording
sessions, in this case as a consequence of chronic
supplementation with micronutrients. The lack of a
chronic effect may therefore reflect a simple attenu-
ation of the acute effects seen following the first dose
of 1RDA + Q10 on Day 1. However, this could equally, in
turn, reflect either increased circulating levels of micronu-
trients as a consequence of 8 weeks administration, which
may have precluded a further acute effect of an additional
dose of micronutrients on Day 56; or it may indicate that
a gross, undetectable change in CBF parameters had
already taken place, attenuating the possibility of any add-
itional acute effects of Day 56’s treatment.
Whilst this study also provides the first demonstration
that simply increasing the demands of cognitive tasks
significantly modulates whole-body metabolic parame-
ters, there was no significant interaction between treat-
ment and specific tasks for either the metabolic or CBF
parameters.
In general, the results with regards the effects of
micronutrients on energy metabolism are broadly in line
with those of Li et al. [16], who examined the effect of
26 weeks supplementation with multivitamin/minerals
on overall resting metabolism in obese females using
ICa, and found that micronutrient supplementation was
associated with a significant increase in resting energy
expenditure and fat oxidation. The specific acute, dose-
related increase in fat oxidation seen here is also consist-
ent with previous ICa studies that have demonstrated an
increase in fat oxidation as a consequence of acute and
chronic administration of calcium [54], acute supple-
mentation with calcium and vitamin D [55] and chronic
vitamin C supplementation [56]. In terms of the mecha-
nisms underlying the effects on overall energy
Table 3 Mean nutritional parameter data (+SEM) from Day 1 and Day 56
Day 1 Day 56 Day 56
ANCOVA
Treatment N Mean SEM Mean SEM Adjusted
mean
SEM
Vitamin C (mg/L) 1RDA + Q10 24 5.30 0.51 6.02 1.23 6.23 0.62
3RDA 26 6.87 1.04 6.42 1.26 6.30 0.59
Placebo 29 6.62 0.61 5.21 0.97 5.14 0.56
Vitamin D (mg/L) 1RDA + Q10 24 25.41 2.40 30.5a 6.22 28.73* 1.51
3RDA 26 24.27 2.19 30.1a 5.90 29.23* 1.45
Placebo 29 20.22 2.22 21.76 4.04 23.97 1.39
Vitamin E (mg/L) 1RDA + Q10 24 11.61 0.56 12.1 2.47 12.00 0.40
3RDA 26 11.73 0.55 12.55 2.46 12.36 0.39
Placebo 29 11.12 0.44 11.36 2.11 11.62 0.37
CoQ10 (μg/L) 1RDA + Q10 24 562.3 46.0 586.3a 119.7 541.8 36.64
3RDA 26 473.1 33.3 452.5 88.8 463.4 34.41
Placebo 29 447.1 26.3 437.8 81.3 464.8 32.89
Iron (μmol/L) 1RDA + Q10 24 1010.7 75.8 951.0 194.1 954.2 75.41
3RDA 26 1064.4 100.1 1054.9 206.9 1042.4 72.55
Placebo 29 992.9 89.6 985.2 183.0 993.7 68.65
Zinc (μmol/L) 1RDA + Q10 24 13.16 0.52 13.65 2.79 13.66 0.31
3RDA 26 13.13 0.28 13.34 2.62 13.35 0.30
Placebo 29 13.26 0.22 13.23 2.46 13.22 0.28
Homocysteine (μmol/L) 1RDA + Q10 24 11.79 0.61 10.54 2.15 10.35* 0.45
3RDA 26 11.83 0.75 9.5a 1.86 9.30* 0.43
Placebo 29 10.76 0.41 11.36 2.11 11.71 0.41
Footnote: a = p < 0.05 from t test comparing means for measures that evinced a significant difference on one way ANOVA of data from the individual day. * = p < 0.05
from t test comparing means for measures that evinced a significant difference on one way ANCOVA of data from Day 56 using Day 1 data as covariate
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expenditure it is notable that vitamins as a group are
directly involved in every aspect of mitochondrial func-
tion including aerobic respiration and cellular energy
production [10–14]. With regards fat oxidation, the ef-
fects of calcium have been attributed in part to modula-
tion of lipolysis and lipogenesis driven by modulation of
levels of circulating 1,25-(OH)2D3 and parathyroid hor-
mone [57], whereas vitamin C is theorised to have its ef-
fect via its role as a cofactor for the biosynthesis of
carnitine, an essential molecule in the oxidation of fatty
acids [56]. Whilst the effects on fat metabolism here
may be predicated simply on the inclusion of calcium,
and vitamins C and D in the micronutrient preparations,
it is not possible to preclude modulation of a multitude
of metabolic parameters by the other vitamin and min-
eral components. It is also worth noting that whereas
the chronic effects of supplementation on fat oxidation
were not significant, the numeric pattern of the data was
consistent with the acute results.
The pattern of CBF parameter effects seen here was for
a treatment related augmentation of the hemodynamic re-
sponses seen during the performance of the active cogni-
tive tasks, with significant increases in total-haemoglobin,
a proxy measure of CBF, seen during four of the five active
task periods. In this instance, due to the counterbalancing
of the order of task performance, the benefits could not be
attributed to specific task demands, and a secondary task
x treatment analysis did not demonstrate an interaction
between the two factors. The modulation of CBF parame-
ters seen here may reflect the requirement to deliver more
metabolic substrates to active neural tissue to support the
increased energy metabolism during task performance,
although the lack of the linear dose–response that was
seen with regards the fat/energy metabolism measures
(for which the 3RDA elicited greater modulation) with
respect to the NIRS measures argues against this. Ra-
ther, the increased hemodynamic response may well be
driven by direct modulation of the neurovascular
coupling of local blood flow to activity. In line with
this, the cardiovascular/vasodilatory properties of sev-
eral micronutrient components of the interventions
here, including vitamin C [24, 25], vitamin B9 [28] and
CoQ10 [32], have previously been attributed to their
roles in the synthesis of nitric oxide, the ubiquitous
signalling molecule that mediates both peripheral vaso-
dilation and neurovascular coupling [3, 4]. The results
here certainly find support from those previous studies
that demonstrated improved peripheral vasodilation
(as assessed by flow mediated dilatation), following
single doses of vitamins B9, C and E [20–23]. Natur-
ally, the question arises as to why the CBF effects were
greater in the treatment containing lower levels of
water soluble vitamins. The obvious answer is that the
1RDA treatment also contained CoQ10, which is
intricately intertwined with the working of the vita-
mins with respect to mitochondrial function [15], and
which may also exert an independent effect in terms
of NO synthesis [32]. Supplementation with CoQ10
has been shown to consistently engender improve-
ments in peripheral endothelial function and other
cardiovascular parameters [32], which would be ex-
pected to co-vary with modified brain vasodilation.
Having said this, the dose administered here was com-
paratively small; 4.5 mg as opposed to 150 mg + in most
of the previous cardiovascular studies. This suggests that
the doses administered in the cardiovascular studies are
unnecessarily large, or that co-administration with vita-
mins relevant to CoQ10 function engenders a syner-
gistic effect. Either way, reference to the nutritional
parameter data showed that the 1RDA + Q10 group
had significantly greater plasma levels of CoQ10 than
the other treatment groups after 56 days supplemen-
tation, suggesting that this dose was adequate to aug-
ment the levels of CoQ10 that were being synthesised
endogenously by individuals during the supplementa-
tion period.
It is also noteworthy that single doses of multi-
vitamin/minerals have previously been shown to modu-
late regional brain activity during a task measuring
focussed attention as measured with functional magnetic
resonance spectroscopy (fMRI) [58], and cerebro-
electrical activity during an attention task as measured
by electroencephalography (EEG) [59].
It is also worth noting that, in this instance, visual in-
spection of the data in Fig. 4 shows that the pattern of
concentration change in haemoglobin concentrations
was for a gradual increase during the absorption period
following all treatments. However, this pattern repre-
sents concentrations simply returning to approximately
zero over this period i.e. reverting to the resting baseline
values. We surmise that the initial reductions in haemo-
globin concentrations immediately after the treatments
reflect the break in ‘quiet’ sitting and the consumption
of the treatment capsules plus water at this point. Given
that all of the reported significant effects of treatment
are directly in comparison to placebo, and that these are
seen only during task completion, it seems unlikely that
any underlying pattern of gradual modulation during the
absorption period could have influenced the results re-
ported here.
In terms of cognitive function, there was no interpret-
able evidence of modulated performance. Whilst a single
measure evinced an isolated statistical difference, there
was no evidence of similar effects from any other meas-
ure, so it seems likely this was just a chance finding. The
lack of cognitive effects may be attributable to several
factors; this was a comparatively small study with less
than 30 participants per group (as opposed to over 100
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per group in previous cognitive studies showing benefits
of multivitamins/minerals [37, 38]; the participants were
fitted with restrictive head gear and a face mask, poten-
tially introducing physical or psychological noise into
the data; and the cognitive outcomes did not have a
baseline that could be used as a covariate, greatly redu-
cing the sensitivity of the assessment.
With regards the nutritional parameters, Vitamin D
was raised following 56 days supplementation with both
multivitamin interventions, and plasma levels of CoQ10
were significantly higher in the 1RDA + Q10 group on
Day 56 (although this did not represent a significant in-
crease on the ANCOVA, possibly due to a trend towards
higher pre-treatment levels in this group on Day 1).
Homocysteine levels were also reduced by both treat-
ments. This is of particular interest as this potentially
neurotoxic amino acid, levels of which correlate posi-
tively with cardiovascular disease, age-associated cogni-
tive decline and dementia [34], can be seen as a marker
of low endogenous levels of a number of B vitamins.
The mean pre-treatment homocysteine levels in this
study were ~11.5 μmol/L on Day 1, a figure that is close
to the 11.7 μmol/L reported as the average in the UK’s
Low Income Diet and Nutrition Survey [57]. The cut-off
point in homocysteine levels associated with greater car-
diovascular disease risk is typically taken as 12 μmol/L.
Some 35 % of the current study’s sample exceeded this
cut-off. These figures, and the fact that supplementation
with simple multi-vitamins significantly reduced homo-
cysteine levels in a dose-related manner (to 10.5 and
9.5 μmol/L respectively for the 1RDA + Q10 and
3RDA treatments), suggest strongly that the cohort
here, who were not selected on the basis of any nu-
tritional parameters, did not have optimal, or even
adequate, nutritional status as a group at the study
outset. Similarly, pre-treatment vitamin D levels in
the cohort of ~20–25 mg/L would be regarded as in-
sufficient by some established cut-off parameters, sug-
gesting that a dose of 200 IU is adequate to rectify
this insufficiency.
With regards the limitations of the study, the most
obvious is that one of the working hypotheses here
was that the treatments might have a greater effect
on CBF parameters and metabolism during the more
difficult tasks. The individual tasks impacted on CBF
parameters and metabolism depending on their cogni-
tive demands, but the effects of the micronutrients
were seen as main effects or interaction effects of
treatment, with no task interactions. In hindsight a
more comprehensive assessment of simple resting me-
tabolism would have been informative. Having said
this, the study provides a very useful starting point
for future studies looking at the metabolic effects of
micronutrients, and in particular it demonstrates that
ICa is a sensitive measure of the somatic metabolic
effects of brain activity. A second limitation of the
study was the inability of the NIRS equipment utilised
here to measure quantitative changes over time. This
makes the absence of acute effects on Day 56 difficult
to interpret, but again, suggests that research using
the more recently introduced quantitative NIRS sys-
tems, which can be used to measure changes over
time, would be informative.
Conclusions
In summary, the results of the current study suggest that
simple supplementation with micronutrients, many of
which are implicated in fat oxidation, mitochondrial me-
tabolism and vasodilation, can increase fat oxidation,
total somatic energy expenditure and cerebral blood-
flow during task performance following a single dose,
and increase energy expenditure following 8 weeks sup-
plementation. These results suggest several conclusions.
The first is that single doses of multi-vitamins/minerals
are capable of modulating metabolic parameters, and
that, furthermore, a single dose of multi-vitamins/
minerals with added CoQ10 can increase the CBF re-
sponse to task performance in the frontal cortex,
thereby increasing the delivery of metabolic substrates
to active neural tissue. Given that the higher 3RDA
dose of water soluble vitamins failed to elicit signifi-
cant modulation of oxygenated and total-haemoglobin
these results suggest that the dosage of CoQ10 (4.5 mg)
administered here was sufficient to act either additively or
synergistically with the co-administered vitamins/minerals
in terms of promoting cerebral vasodilation. Second,
the results suggest that multivitamin/mineral supple-
mentation over a longer period of time (in this case
56 days) is capable of significantly increasing overall
energy metabolism/expenditure. Given that there was
no interaction between task demands and treatment
related effects, it is possible that these effects could
also be seen at rest, and likely that they would be evi-
dent during physical exercise. These possibilities de-
serve further research attention.
Finally, the logical conclusion that can be garnered
from the results here is that, if it is possible to benefi-
cially modulate core physiological processes such as en-
ergy metabolism and cerebral blood-flow by simply
administering vitamins and other micronutrients to
healthy members of the population, then it must be the
case that the nutritional status of the sample, and by
implication the general population, is inadequate. This
suggestion is supported by the comparatively high
pre-treatment levels of homocysteine seen across the
cohort here. If it is the case that our results reflect
wide-spread nutritional insufficiency, and given the
challenge that shifting the general population’s dietary
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patterns poses, then, in the absence of a healthy diet,
supplementation with vitamins and other micronutri-
ents may prove a useful method of recharging nutri-
tional status for a section of the population.
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the control tapping task and 5 task periods on Day 1 and Day 56. Table S3.
Cognitive task performance scores (mean plus SEM) on Day 1 and Day 56.
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